Jonathan E. Lim, M.D.
President, Chief Executive Officer and member of the Board of Directors
Dr. Jonathan Lim became employee number five when he joined Halozyme in May 2003 as President and CEO. He was elected to the Board of Directors in October 2003 and served as Chairman from April 2004 to December 2005. Under Dr. Lim’s leadership, Halozyme has raised over $225 million from financings and corporate partnerships, signed major alliances with Roche and Baxter, received two FDA approvals, for Hylenex® and Cumulase®, and transitioned into a Nasdaq listed company with approximately 140 employees. From 2001 to 2003, Dr. Lim was a management consultant at McKinsey & Company, where he specialized in the health care industry, serving a wide range of companies from start-ups to Fortune 500 multinationals in the biopharmaceutical, medical products, and payor/provider segments. From 1999 to 2001, Dr. Lim was a National Institutes of Health Postdoctoral Fellow conducting clinical outcomes research at Harvard Medical School. Dr. Lim’s professional experience also includes clinical training in general surgery at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center; Founder and President of a health care technology start-up; Founding Editor-in-Chief of the McGill Journal of Medicine; basic science and clinical research at the Salk Institute for Biological Studies and the Massachusetts Eye and Ear Infirmary; and membership on the strategic planning committee of the American Medical Association from 2002 to 2005. Dr. Lim earned his B.S., with honors, and M.S. in molecular biology from Stanford University, his M.D. from McGill University, and his M.P.H. in health care management from Harvard University.
Gregory I. Frost, Ph.D.
Vice President, Chief Scientific Officer and member of the Board of Directors
Dr. Gregory Frost co-founded Halozyme in 1999 and has spent more than fifteen years conducting research on the hyaluronidase family of enzymes. From 1998 to 1999, he was a Senior Research Scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work on developing the hyaluronidase technology. Prior to SKCC, his research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning, and characterization of the human hyaluronidase gene family, and the discovery of several metabolic disorders. He has authored multiple scientific peer-reviewed and invited articles in the hyaluronidase field and is an inventor on several key patents. Dr. Frost’s prior experience includes serving as a scientific consultant to a number of biopharmaceutical companies, including Q-Med AB, BioPhausia AB and Active Biotech AB. Dr. Frost is registered to practice before the U.S. Patent and Trademark Office, and earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, and his Ph.D. in the Department of Pathology at the University of California, San Francisco, where he was an Achievement Rewards for College Scientists Scholar.
Kurt Gustafson
Vice President, Chief Financial Officer
Mr. Kurt Gustafson joined Halozyme in 2009 with extensive operational and managerial experience in financial planning and analysis, accounting, treasury, and international responsibility gained during his 18 years with Amgen. In his most recent position, as Vice President, Manufacturing Finance, Mr. Gustafson had financial responsibility for each of Amgen’s worldwide manufacturing sites and the Cost Accounting Group. He was responsible for the financial planning, cost accounting, capital planning, and procurement activities at each of these sites from 2006 to 2009. From 2004 to 2006, Mr. Gustafson was Vice President, Finance and CFO of Amgen Europe, responsible for financial planning and accounting for European operations. Stationed in Switzerland, Kurt was responsible for Amgen’s International Operations, which spanned Europe, the Middle East, Eastern Europe, North Africa, and Australia. From 2000 to 2004, Mr. Gustafson headed up Corporate Financial Planning and Analysis, most recently as Vice President, Corporate Financial Planning & Analysis. In this role, he was responsible for worldwide consolidation of the company’s forecasts. He also led the Corporate Business Analysis group, which provided financial and decision support to the Product Strategy Teams. From 1991 to 1998, Mr. Gustafson held multiple positions in Amgen’s Treasury group with increasing levels of responsibility, most recently serving as Treasurer, where he oversaw the tax department and the customer finance group. Prior to joining Amgen, Mr. Gustafson worked in public accounting as Staff Auditor at Laventhol & Horwath in Chicago. He earned a B.A. in accounting from North Park University in Chicago and an M.B.A from UCLA.
Jonathan Leff, M.D.
Vice President, Chief Medical Officer
Dr. Jonathan Leff joined Halozyme in 2009 with extensive experience in clinical development and medical affairs, and a proven track record in pharmaceutical product development from early stage molecules through global filing, approval and launch. From 2007 to 2009, Dr. Leff served at Roche as Vice President and Global Head, Inflammation Clinical Development and Disease Biology Leadership Team member. While at Roche, he helped lead the development of products for inflammation, including managing the clinical development department on a global basis for inflammation products in registration phase development, such as MabThera®/Rituxan®, ocrelizumab, and Actemra®. From 2002 to 2007, Dr. Leff was at Amgen Inc., where he served most recently as Vice President, North American Medical Affairs. His responsibilities included leadership of a department of 500 people, and the oversight of 5 therapeutic areas, 8 marketed products, and 4 late stage pipeline products, which involved the support and growth of 5 blockbuster brands: Neupogen®, Neulasta®, Epogen®, Aranesp®, and Enbrel®. In his prior role at Amgen, Dr. Leff was Senior Medical Director and Department Head of Osteoporosis Research, where he was responsible for conducting Phase 2 and 3 osteoporosis clinical trials for denosumab in over 10,000 patients, including a 7,800 patient fracture study. From 1994 to 2002, Dr. Leff was at Merck & Co., where he performed Phase 1 through Phase 4 clinical research studies for Singulair®, a leukotriene receptor antagonist, which resulted in a global filing and regulatory approval. From 1990 to 1994, Dr. Leff was a faculty member in the Pulmonary Division of the University of Colorado School of Medicine, with responsibilities for patient care, teaching, and basic research. Dr. Leff is board certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. He received his B.A. in chemistry and M.D. from the University of Pennsylvania.
Robert J. Little
Vice President, Chief Commercial Officer
Mr. Robert Little joined Halozyme in 2006 with extensive experience in the pharmaceutical industry in general management, commercial operations, sales and marketing and business development. From 2003 to 2006, Mr. Little was Senior Vice President of Commercial Operations at Neurocrine Biosciences, where he was responsible for building and managing the sales and marketing functions. During his tenure, Mr. Little put in place a fully integrated commercial organization, including a marketing team, a 200-person CNS sales force, and full logistical and infrastructure support in order to co-detail Zoloft® with Pfizer and in preparation for the introduction of Indiplon®. From 1985 to 2003, Mr. Little was at Pharmacia, Inc. where his most recent position was Group Vice President, Diversified Products. His responsibilities included managing Pharmacia's Diversified Products business, as well as forming a new global business unit merging pricing, reimbursement, and health outcomes groups to focus on current industry issues, pricing, and drug values. From 1999 to 2001, Mr. Little was Group Vice President, Specialty Products and worldwide head of a $2.5 billion, global specialty products business (ophthalmology, endocrinology, neurology and others). Mr. Little previously held a number of positions within Pharmacia, including President and Managing Director of Pharmacia in Milan, Italy, President of Pharmacia & UpJohn in Canada, and President of Pharmacia, Inc. in Canada. Prior to joining Pharmacia, he held positions at Adria Laboratories and Miles Laboratories/Bayer AG in the U.K., Italy, and the U.S. Mr. Little earned his degree in economics and finance from the West London Business School, Ealing Technical College.
Walter H. Bee, Ph.D.
Vice President, Preclinical Development
Dr. Walter Bee joined Halozyme in 2007 as Vice President, Preclinical Development. Dr. Bee has published numerous scientific articles and papers that reflect his extensive experience with both small and large molecules, across all phases of preclinical development, including regulatory filings. Prior to Halozyme, Dr. Bee was Director of Toxicology, Pathology and Laboratory Animal Medicine at Johnson & Johnson, where he was responsible for toxicology and histopathology on the west coast. From 2002 to 2006, he was Director of Toxicology at Scios, Inc. prior to its acquisition by Johnson & Johnson. At Scios, his responsibilities included implementation of preclinical plans and oversight of non-clinical safety, toxicology and pharmacokinetic studies. As a member of the Global Preclinical Leadership Team, he oversaw the design and roll-out of the J&J Global Preclinical Development model. Dr. Bee represented Preclinical Development at scientific congresses and at meetings with clinical investigators, potential corporate licensing partners, and regulatory authorities. He has also held leadership positions at leading contract research organizations and biopharmaceutical companies, such as Sierra Biomedical (a Charles River company), SNBL USA, CoCensys and Covance. Dr. Bee earned his bachelor’s and master’s degrees in biology and his Ph.D. in zoology from the University of Münster, Germany.
Igor P. Bilinsky, Ph.D.
Vice President, Business Development and Special Operations
Dr. Igor Bilinsky joined Halozyme in 2007 as Executive Director of Corporate Development and Special Operations and was promoted to Vice President, Business Development and Special Operations in January 2008. Prior to Halozyme, Dr. Bilinsky was Chief Executive Officer at Androclus Therapeutics, a venture-funded biotechnology company developing novel therapeutics for autoimmune and inflammatory diseases. He joined Androclus as Chief Operating Officer in 2004 and served as CEO from 2005 to 2007. His professional background also includes experience from 1999 to 2004 as a management consultant, project leader and principal in the healthcare practice of the Boston Consulting Group, where he advised companies in the biotechnology, pharmaceutical and life science industries on strategic, operational and M&A issues. His clients included a diverse group of leading pharmaceutical and biotechnology companies. Previously, Dr. Bilinsky also worked in R&D at Symyx Technologies and MIT Lincoln Laboratory. Dr. Bilinsky received his B.S. in physics from the Moscow Institute of Physics and Technology and his Ph.D. in physics from the Massachusetts Institute of Technology.
James E. Cartoni
Vice President, Legal
Mr. James Cartoni joined Halozyme in 2008 as Vice President, Legal. His responsibilities include overseeing various legal matters, including the negotiation and completion of agreements, corporate governance matters, securities compliance, and the coordination and management of outside legal counsel. Prior to joining Halozyme, Mr. Cartoni was a corporate securities partner at DLA Piper, the world’s largest law firm, where he represented numerous public and private companies in areas such as financing transactions, corporate compliance, mergers & acquisitions and general business matters. DLA Piper is Halozyme’s primary outside corporate counsel and Mr. Cartoni has represented Halozyme since 2004. He also served as the Co-Chair of the Legal and Finance Committee for the 2008 U.S. Open at Torrey Pines Golf Course. Mr. Cartoni obtained his B.A. in political science from Occidental College and his Juris Doctor degree from the University of California - Hastings College of the Law in 1998.
William J. Fallon
Vice President, Manufacturing & Operations
Mr. William Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. His responsibilities include oversight of all aspects of internal and external manufacturing and facilities operations, as well as bioprocess development. Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in marine science and a B.A. in biology from Long Island University, and an M.S. in biology from Northeastern University.
Michael F. Haller, Ph.D.
Vice President, Alliance Management & Head, Drug Delivery Franchise
Dr. Michael Haller directs key alliances for Enhanze™ technology with Roche and Baxter, and sets and executes the strategy to attract future Enhanze partners, support current alliances, and broaden the PH20 platform knowledge base. Previously, as Vice President of Alliance Management and Portfolio Development, he was responsible for directing Halozyme’s strategic alliances, evaluating and prioritizing Halozyme’s portfolio of programs, and leading Program and Project Management. Upon joining Halozyme in 2004, and through 2006, Dr. Haller served as Halozyme’s Senior Director of Corporate Development and Portfolio Management, with responsibility for compound in-licensing and leadership of internal project teams. From 2001 to 2004, Dr. Haller was a management consultant at McKinsey & Company, where he focused on complex health care issues for Fortune 500 companies involved in branded and generic pharmaceutical, biotechnology, medical device, and payor/provider activities. He has published several articles in peer-reviewed journals, has presented at various scientific conferences, and is the co-inventor on multiple patents. Dr. Haller earned a B.S. with honors in biomedical engineering from The Johns Hopkins University, an M.S. in chemical engineering from Cornell University, and a Ph.D. in biomedical engineering from The Johns Hopkins University School of Medicine.
Don A. Kennard
Vice President, Regulatory Affairs & Quality Assurance
Mr. Don Kennard joined Halozyme in 2004 with extensive senior management experience in the fields of regulatory affairs (RA), clinical programs, and quality assurance (QA). He has worked directly with the FDA, as well as regulatory authorities of various foreign ministries of health, to secure registration, authorize commercialization, and successfully implement quality programs, for a broad range and extensive number of product approvals across pharmaceuticals, biologics, medical devices and diagnostics. Prior to joining Halozyme, Mr. Kennard served as Vice President of Worldwide RA/QA at Quidel, Inc., a manufacturer of diagnostic products, where he led the RA/QA and clinical functions, while also establishing a Quality System CE marking program that enabled Quidel to expand and sustain sales in the European Union. From 1991 to 2001, he was Vice President of Research and Development, Regulatory Affairs, Clinical and Quality Assurance for Nobel Biocare, Inc. and Steri-Oss (acquired by Nobel Biocare). From 1981 to 1991, Mr. Kennard was Director of RA/QA at Allergan, Inc. for prescription and OTC ophthalmic and dermatological drugs, injectable drugs, biotechnology products and ophthalmic products. Prior to Allergan, he was Director of Quality Control at B. Braun. Mr. Kennard holds a B.S. in microbiology from the University of California, Long Beach.
Michael J. LaBarre, Ph.D.
Vice President, Product Development
Dr. Michael LaBarre joined Halozyme in 2008 and oversees all of Halozyme’s product development efforts, bringing strong expertise in chemistry, manufacturing and controls (CMC) based on his extensive experience in the biotechnology industry for both biologics and small molecules. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (previously IDEC), where he had responsibility for analytical and formulation development, protein purification, and biochemical characterization supporting numerous IND and BLA submissions, including those for Rituxan® and Zevalin®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group. He began his career at Hybritech, where he held positions in regulatory affairs and manufacturing technical support, focusing on radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College and his Ph.D. in bioinorganic chemistry from the University of Arizona.
Douglas B. Muchmore, M.D.
Vice President, Endocrinology Clinical Development
Dr. Douglas Muchmore joined Halozyme in 2008 with extensive expertise in clinical research trial design and implementation, the practice of endocrinology, and all stages of clinical drug development in the field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical Fellow II on the Insulins and Devices Team and a member of the Diabetes Platform Team at Eli Lilly and Co. He acted as the key scientific developer and lead medical negotiator for FDA interactions for AIR® Insulin, Lilly’s inhaled insulin program. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase 3. Dr. Muchmore’s responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme’s proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Dr. Muchmore served on the Evista® Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, University of California, San Diego, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore received his A.B. in biological sciences from Stanford University, his M.D. from UCSD, and his internal medicine residency at the University of Washington and the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism at University Hospital, Seattle in 1982.
David A. Ramsay
Vice President, Corporate Development
Mr. David Ramsay joined Halozyme in 2003 as Chief Financial Officer. He has over 20 years of corporate financial experience spanning several industries. In 2009 Mr. Ramsay was named Vice President, Corporate Development. From 2000 to 2003, he was Vice President, Chief Financial Officer of Lathian Systems, a provider of technology-based sales solutions for the life sciences industry. Prior to Lathian, Mr. Ramsay was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company. Mr. Ramsay joined ICN in 1998 from ARCO, where he spent four years in various financial roles, most recently serving as Manager of Financial Planning & Analysis for the company’s 1,700-station West Coast Retail Marketing Network. Prior to ARCO, he served as Vice President, Controller for Security Pacific Asian Bank, a subsidiary of Security Pacific Corporation. He began his career as an auditor at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay served as Chairman of the Audit Committee and on the Board of Directors for Axxora Life Sciences, Inc., a privately held, worldwide research reagent company which was acquired by Enzo Biochem in 2007. Mr. Ramsay graduated from the University of California, Berkeley, with a B.S. in business administration and earned his M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.
H. Michael Shepard, Ph.D.
Vice President, Discovery Research
Dr. H. Michael Shepard joined the company in 2009 as Vice President, Discovery Research with extensive experience in the biotechnology industry. Following his postdoctoral training, Dr. Shepard joined Genentech in 1980, where he participated in many of the early programs that transformed Genentech into a commercial success. Among his most important accomplishments, his team identified a key mechanism by which tumor cells can escape the host immune system. This work led to the discovery of the breast cancer drug, Herceptin™ (trastuzumab), which was designed to attack HER2 positive breast cancers by inhibiting their growth and enhancing their sensitivity to the immune system. In 2007, Dr. Shepard shared the Warren Alpert Prize from Harvard Medical School in recognition of this achievement. In addition, Dr. Shepard built successful programs at various biotechnology companies in diverse areas including antibiotics, cancer gene therapy and receptor fusion proteins. During 1992 to 1996, he served as Vice President of Research and Chief Scientific Officer at Canji, Inc. and, most recently, was founder and President of Receptor BioLogix, Inc. Dr. Shepard received his bachelor’s degree in zoology from UC Davis and his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University, where he was a Damon Runyon Cancer Research Foundation Fellow.
